BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 17301556)

  • 1. [Operational aspect of participation in the multi-national clinical trials from the foreign pharmaceutical company's standpoint].
    Namazu K
    Gan To Kagaku Ryoho; 2007 Feb; 34(2):328-30. PubMed ID: 17301556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Why multi-national clinical trials now?--Industry perspective].
    Miki S
    Gan To Kagaku Ryoho; 2007 Feb; 34(2):293-6. PubMed ID: 17301547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Our policy and future tasks related to ICH in anti-cancer drug development--a discussion from the viewpoint of an enterprise].
    Ekimoto H
    Gan To Kagaku Ryoho; 1997 Jan; 24(2):229-37. PubMed ID: 9030236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Participation in the international multi-countries study-operational issues from company view point].
    Hada S
    Gan To Kagaku Ryoho; 2007 Feb; 34(2):324-7. PubMed ID: 17301555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Post launch studies].
    Akaza H; Ohashi Y; Shimada Y; Ikeda T; Saijo N; Isonishi S; Hirao Y; Tsuruo T; Tsukagoshi S; Sone S; Nakamura S; Kato M; Mikami O; von Euler M; Blackledge G; Milsted B; Vose B
    Gan To Kagaku Ryoho; 2002 Nov; 29(11):2037-48. PubMed ID: 12465411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Implementation of new Japanese GCP and the quality of clinical trials--from the standpoint of the pharmaceutical industry].
    Ebi O
    Gan To Kagaku Ryoho; 1997 Oct; 24(13):1883-91. PubMed ID: 9350232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Participation to international registration trials--from the investigator's standpoint].
    Ohtsu A
    Gan To Kagaku Ryoho; 2007 Feb; 34(2):297-300. PubMed ID: 17301548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Impact of rapid advancement of international standardization on technical requirements for new drug registration].
    Kurokawa T
    Gan To Kagaku Ryoho; 1996 Apr; 23(5):509-16. PubMed ID: 8678507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Globalization of clinical trials].
    Akaza H; Fukuoka M; Ohtsu A; Usami M; Ikeda T; Aiba K; Isonishi S; Ohashi Y; Saijo N; Sone S; Tsukagoshi S; Tsuruo T; Kato M; Mikami O; Dong RP; von Euler M; Blackledge G; Stribling D
    Gan To Kagaku Ryoho; 2003 Apr; 30(4):555-65. PubMed ID: 12722692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The role of the Japan Clinical Oncology Group].
    Ohe Y; Saijo N
    Gan To Kagaku Ryoho; 2000 Jul; 27(8):1127-32. PubMed ID: 10945006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characteriation of clinical data packages using foreign data in new drug applications in Japan.
    Tanaka M; Nagata T
    Clin Pharmacol Ther; 2008 Sep; 84(3):340-6. PubMed ID: 17786162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent changes in quality in Japanese clinical trials.
    Saito K; Kodama Y; Ono S; Fujimura A
    Ann Pharmacother; 2004 Jan; 38(1):151-5. PubMed ID: 14742810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Improving the infrastructure for clinical trials in Japan].
    Nakano S
    Gan To Kagaku Ryoho; 1999 Jan; 26(2 Suppl):225-30. PubMed ID: 9987523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [International clinical trials: perspectives of clinical research coordinators].
    Aotani E
    Gan To Kagaku Ryoho; 2007 Feb; 34(2):308-11. PubMed ID: 17301551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Development of highly specialized clinical drug trial units within health care institutions].
    Stanimirović V; Babić M; Nikolić D; Cucak S; Nikolić A
    Srp Arh Celok Lek; 2000; 128(7-8):253-8. PubMed ID: 11089432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical trials profile: professionals and sites.
    Paschoale HS; Barbosa FR; Nita ME; Carrilho FJ; Ono-Nita SK
    Contemp Clin Trials; 2010 Sep; 31(5):438-42. PubMed ID: 20601160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and quality in clinical trials. Requirements to the investigator site. European Economic Community.
    Friederichs E; Spitzer SG; Bach R
    Arzneimittelforschung; 1994 Feb; 44(2):182-4. PubMed ID: 8147953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical trials registries: towards improved access to therapeutic data.
    Prescrire Int; 2008 Dec; 17(98):256-9. PubMed ID: 19425275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic advantage of pharmacogenomics - clinical trials with genetic information.
    Ohashi W; Mizushima H; Tanaka H
    Stud Health Technol Inform; 2008; 136():585-90. PubMed ID: 18487794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.